Skip to main content

Table 3 Postoperative course and complications (N = 70)a

From: The Carpentier-Edwards Perimount Magna mitral valve bioprosthesis: intermediate-term efficacy and durability

Hospital LOS,b days 11.6 ± 0.8
Cardiogenic shockc 6 (8.6 %)
IABP use 2 (2.9 %)
Tracheostomy 4 (5.7 %)
Any renal failure 17 (24 %)
Renal failure requiring dialysis 6 (8.6 %)
Reoperation for bleed 4 (5.7 %)
AF 50 (71 %)
Heart block 19 (27 %)
 Transient 16 (23 %)
 Permanent pacer 3 (4.2 %)
Wound infection 1 (1.4 %)
Cardiac arrest 3 (4.3 %)
In-hospital death 5 (7.1 %)
Stroke 2 (2.9 %)
Valve-related complications  
 Thrombosis 0 (0 %)
 Dehiscence 0 (0 %)
 LVOTOd 1 (1.4 %)
 Vegetations 0 (0 %)
 AV groove disruption 1 (1.4 %)
  1. AF atrial fibrillation, AV atrioventricular, IABP intraaortic balloon pump, LOS length of stay, LVOTO left ventricular outflow tract obstruction
  2. aContinuous variables expressed as mean ± standard error of the mean (SE); categorical variables, as n (percentage)1
  3. bData available for only 65 patients
  4. cData available for only 69 patients
  5. dRequired reoperation at 2 years